Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.

Gut microbes·2026

Same author

Clinical and Demographic Determinants of Adherence to Digital Monitoring in Cirrhosis: A Prospective Cohort Analysis.

Research square·2026

Same author

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients with Severe Alcohol-associated Hepatitis.

Clinical and translational gastroenterology·2026

Same author

Sociodemographic disparities in Hepatitis C care utilization and testing in the United States.

Communications medicine·2026

Same author

Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Cancer research communications·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib: where do we go from here?

Abby B Siegel¹, Sonja K Olsen, Arthur Magun

¹Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. aas54@columbia.edu

Hepatology (Baltimore, Md.)

|June 26, 2010

Summary

This summary is machine-generated.

Sorafenib is a key treatment for hepatocellular carcinoma (HCC). Understanding HCC molecular pathways drives new targeted therapies, improving patient outcomes.

Related Experiment Videos

Last Updated: Jun 12, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

Hepatocellular carcinoma (HCC) research
Molecular pathogenesis
Targeted cancer therapy

Background:

Sorafenib approval marks a milestone in HCC treatment.
Advances in understanding HCC molecular pathogenesis.
Multidisciplinary approach is crucial for HCC management.

Purpose of the Study:

Review molecular pathogenesis of HCC.
Explore current and future targeted treatments.
Discuss integration of novel therapies with existing approaches.

Main Methods:

Literature review of HCC pathogenesis.
Analysis of targeted treatment pathways.
Synthesis of current and emerging therapeutic strategies.

Main Results:

Detailed description of HCC molecular pathways.
Overview of approved and investigational targeted therapies.
Discussion on synergistic potential of new treatments.

Conclusions:

Novel targeted therapies offer promise for HCC treatment.
Integration of targeted therapies requires a multidisciplinary approach.
Continued research into HCC molecular mechanisms is vital.